Grant Michael, Larijani Mani
Program in Immunology and Infectious Diseases, Division of Biomedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, A1B 3V6, Canada.
AIDS Res Ther. 2017 Sep 12;14(1):44. doi: 10.1186/s12981-017-0173-8.
APOBEC3G (A3G) and APOBEC3F (A3F) are DNA-mutating enzymes expressed in T cells, dendritic cells and macrophages. A3G/F have been considered innate immune host factors, based on reports that they lethally mutate the HIV genome in vitro. In vivo, A3G/F effectiveness is limited by viral proteins, entrapment in inactive complexes and filtration of mutations during viral life cycle. We hypothesized that the impact of sub-lethal A3G/F action could extend beyond the realm of innate immunity confined to the cytoplasm of infected cells. We measured recognition of wild type and A3G/F-mutated epitopes by cytotoxic T lymphocytes (CTL) from HIV-infected individuals and found that A3G/F-induced mutations overwhelmingly diminished CTL recognition of HIV peptides, in a human histocompatibility-linked leukocyte antigen (HLA)-dependent manner. Furthermore, we found corresponding enrichment of A3G/F-favored motifs in CTL epitope-encoding sequences within the HIV genome. These findings illustrate that A3G/F-mediated mutations mediate immune evasion by HIV in vivo. Therefore, we suggest that vaccine strategies target T cell or antibody epitopes that are not poised for mutation into escape variants by A3G/F action.
载脂蛋白B mRNA编辑酶催化多肽样蛋白3G(A3G)和载脂蛋白B mRNA编辑酶催化多肽样蛋白3F(A3F)是在T细胞、树突状细胞和巨噬细胞中表达的DNA突变酶。基于它们在体外可使HIV基因组发生致死性突变的报道,A3G/F被认为是先天性免疫宿主因子。在体内,A3G/F的有效性受到病毒蛋白、被困于无活性复合物以及病毒生命周期中突变过滤的限制。我们推测,亚致死性A3G/F作用的影响可能超出局限于受感染细胞胞质的先天性免疫范围。我们检测了来自HIV感染者的细胞毒性T淋巴细胞(CTL)对野生型和A3G/F突变表位的识别,发现A3G/F诱导的突变以人组织相容性连锁白细胞抗原(HLA)依赖的方式,绝大多数情况下会减弱CTL对HIV肽段的识别。此外,我们在HIV基因组内的CTL表位编码序列中发现了A3G/F偏好基序的相应富集。这些发现表明,A3G/F介导的突变在体内介导了HIV的免疫逃逸。因此,我们建议疫苗策略应针对不会因A3G/F作用而突变为逃逸变体的T细胞或抗体表位。